COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,720 Articles (22,502 medRxiv, 8,218 bioRxiv)

Most recent first Previous |  Page 110: Articles 1091-1100  | Next

A systematic review of psychological factors influencing attitudes and intentions toward, and uptake of, Covid-19 vaccines in adolescents
Pitt, A., Amlot, R., Heffernan, C., Rubin, G. J., Smith, L. E.
10.1101/2024.09.17.24313392 — Posted: 2024-09-17
PangeBlocks: customized construction of pangenome graphs via maximal blocks
Bonizzoni, P., Avila Cartes, J. E., Ciccolella, S., Della Vedova, G., Denti, L.
10.1101/2024.09.17.613426 — Posted: 2024-09-17
Affinity tag free purification of SARS-Cov-2 N protein and its crystal structure in complex with ssDNA
Maiti, A., Matsuo, H.
10.1101/2024.09.16.613250 — Posted: 2024-09-17
In computer explore The neutralization mechanism of Amubarvimab and Romlusevimab against SARS-COV-2 mutants
Huan, X., Gao, H.
10.1101/2024.09.14.613008 — Posted: 2024-09-17
A Multi-City COVID-19 Categorical Forecasting Model Utilizing Wastewater-Based Epidemiology
Rankin, N. A., Saiyed, S., Du, H., Gardner, L. M.
10.1101/2024.09.16.24313752 — Posted: 2024-09-16
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Phan, T., Ribeiro, R., Edelstein, G. E., Boucau, J., Uddin, R., Marino, C., Liew, M. Y., Barry, M., Choudhary, M. C., Tien, D., Su, K., Reynolds, Z., Li, Y., Sagar, S., Vyas, T. D., Kawano, Y., Sparks, J. A., Hammond, S. P., Wallace, Z., Vyas, J. M., Li, J. Z., Siedner, M. J., Barczak, A. K., Lemieux, J. E., Perelson, A. S.
10.1101/2024.09.13.613000 — Posted: 2024-09-16
Covidization and decovidization of the scientific literature and scientific workforce
Ioannidis, J., Collins, T. A., Bendavid, E., Baas, J.
10.1101/2024.09.13.24313660 — Posted: 2024-09-15
Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults with hybrid immunity against COVID-19: a multicenter, partially randomized, platform trial in China
Jia, S., Liu, Y., He, Q., Pan, H., Liang, Z., Zhou, J., Pan, Y., Liu, S., Wu, J., Yang, K., Zhang, X., Zhao, Y., Li, S., Zhang, L., Chen, L., Yao, A., Lu, M., Mao, Q., Zhu, F., Li, J.
10.1101/2024.09.14.24313671 — Posted: 2024-09-15
Modeling the effects of COVID-19 mobility disruptions on RSV transmission in Seattle, Washington
Srinivas Duddu, A., Elgamal, I., Camacho-Mateu, J., Holubowska, O., Rella, S. A., Bents, S. J., Viboud, C., Hansen, C. L., Pullano, G., Perofsky, A. C.
10.1101/2024.09.13.24313667 — Posted: 2024-09-15
Variant Evolution Graph: Can We Infer How SARS-CoV-2 Variants are Evolving?
Das, B., Heath, L. S.
10.1101/2024.09.13.612805 — Posted: 2024-09-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).